Biomedical companies in Binhai New Area in North China’s Tianjin Municipality are regarded as main driving forces to achieve the industry’s ambitious prospect to sat on 100 billion yuan ($15.44 billion) by 2025.

The new area has gathered together more than 1,500 biomedical companies, which have made scientific achievements in key areas, such as vaccines, recombinant proteins, stem cells, and high-end medical devices.

Asymchem, one of China's top ten CDMO companies, has made impressive strides since founding in 1999, providing R&D and one-stop production services to the world’s top pharmaceutical companies.

At present, the company has over ten subsidiaries across the globe for research, production and selling, with total market value over 100 billion yuan and 6,200 employees. Four of them are in Binhai’s Tianjin Economic-Technological Development Area(TEDA), valuing 7.1 billion yuan.

Asymchem is committed to supporting emerging biotech companies and smaller, specialty pharma, and the launch of new drugs.

It provides solutions range from early clinical stage to commercial stage, including R&D and cGMP production of advanced intermediates, APIs, formulations, as well as clinical research services.

Asymchem’s R&D chemical development team consists of more than 2000 highly-qualified scientists with experience in the most challenging syntheses.

It once took only 42 days to produce phase III clinical drugs for its customer, saving a blockbuster drug with annual sales of 3 billion US dollars at least 6 months of time to market.

Established with a registered capital of 600 million yuan in June 2006, WuXi AppTec( Tianjin) is a full wholly-owned subsidiary of Wuxi AppTec ("A+H" dual listing company),  a global provider of research and development and manufacturing services enabling healthcare companies.

Being innovation-driven and customer-focused, WuXi AppTec helps partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions.

With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 5,200 collaborators from over 30 countries to improve the health of those in need – and to realize the company’s vision that "every drug can be made and every disease can be treated."

Its Tianjin company has more than 3,000 employees and 2,800 scientific researchers, over half of who hold master’s and doctoral degrees; the main business revenue in 2019 is one billion yuan.

In 2020, Binhai 's biomedical industry output value sat at 40.25 billion yuan, accounting for 64.2 percent of the city's total biomedical output.

By 2025, the new area will have been shaped into a highly innovative and internationally competitive drug development and drug manufacturing piloting zone, characterized by its comprehensive subdivisions and variety of complete medical products.

Tens of billions of yuan’s worth of well-designed industry clusters dedicated respectively to pharmaceutical, biotechnology, medical device, diagnostics and modern Chinese medicine will take shape and be formed in the area.

Smart technologies have gradually been applied to facilitate the upgrading and modernization of production and manufacturing. The area has also seen an increase in international cooperation and roles.

Binhai is now attracting international talents to further boost its biomedical industry.